

UNCLASSIFIED

AD NUMBER
ADB176298
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to DoD only; Specific Authority; 14 Aug 1993. Other requests shall be referred to Commander, U.S. Army Medical Research and Development Command, Attn: SGRD-RMI-S, Fort Detrick, Frederick, MD 21702-5012.
AUTHORITY
USAMRMC/MCMR-RMI-S ltr, 29 Aug 1995

THIS PAGE IS UNCLASSIFIED



DEPARTMENT OF THE ARMY
U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
FORT DETRICK, MARYLAND 21702-5012



REPLY TO
ATTENTION OF:
MCMR-RMI-S

(70-1)

ERRATA

AD-B176298

29 Aug 95

MEMORANDUM FOR Administrator, Defense Technical Information
Center, ATTN: DTIC-HDS/William Bush,
Cameron Station, Building 5, Alexandria, VA
22304-6145

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limited distribution statement on technical report for Contract Number DAMD17-93-C-3083. Request the limited distribution statement for AD Number ~~AD176298~~ be changed to "Approved for public release; distribution unlimited." A copy of this report should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus,
DSN 343-7322.

Gary R. Gilbert

GARY R. GILBERT
COL, MS

Deputy Chief of Staff
for Information Management

REPRODUCTION QUALITY NOTICE

This document is the best quality available. The copy furnished to DTIC contained pages that may have the following quality problems:

- **Pages smaller or larger than normal.**
- **Pages with background color or light colored printing.**
- **Pages with small type or poor printing; and or**
- **Pages with continuous tone material or color photographs.**

Due to various output media available these conditions may or may not cause poor legibility in the microfiche or hardcopy output you receive.

If this block is checked, the copy furnished to DTIC contained pages with color printing, that when reproduced in Black and White, may change detail of the original copy.

AD-B176 298



L
②

CONTRACT NO: DAMD17-93-C-3083

TITLE: NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST BIOLOGICAL TOXINS

PRINCIPAL INVESTIGATOR: Mark C. Glassy, Ph.D.

CONTRACTING ORGANIZATION: Hygeia Pharmaceuticals, Inc.
6555 Nancy Ridge Drive, #300
San Diego, California 92121

REPORT DATE: August 14, 1993

TYPE OF REPORT: Phase I Final Report

DTIC
SELECTE
SEP 23 1993
S B D


PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to DOD Components only, Specific Authority, August 14, 1993. Other requests shall be referred to the Commander, U.S. Army Medical Research and Development Command, ATTN: SGRD-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

93 9 22 020

93-22055



REPORT DOCUMENTATION PAGE

DAM No. 0704-0183

The number of pages in this report and the amount of information is estimated to average 1 hour per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 14, 1993	3. REPORT TYPE AND DATES COVERED Phase I Final (2/16/93-8/15/93)	
4. TITLE AND SUBTITLE Neutralizing Monoclonal Antibodies Against Biological Toxins			5. FUNDING NUMBERS Contract No. DAMD17-93-C-3083	
6. AUTHOR(S) Mark C. Glassy, Ph.D.			65502A 30665502M802.S4.274 WUDA336206	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Hygeia Pharmaceuticals, Inc. 6555 Nancy Ridge Drive, #300 San Diego, California 92121			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research & Development Command Fort Detrick Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES SBIR 92.2.I				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Distribution authorized to DOD Components only, Specific Authority, August 14, 1993. Other requests shall be referred to the Commander, U.S. Army Medical Research & Development Command, Fort Detrick, Frederick, MD 21702-5012			12b. DISTRIBUTION CODE <i>attn: SGRD-RMI-S</i>	
13. ABSTRACT (Maximum 200 words) This SBIR project was broken down into two separate phases. The first phase served to demonstrate that a human immune response could be generated to the A-chain of ricin. The second phase centered on the immortalization of this immune response. A human immune response, though weak, to ricin A-chain was observed using IVI protocols. Different patient's splenocytes were found to respond differently to in vitro immunization protocols with ricin A-chain as an antigen. To further improve the human immune response to rAC, different adjuvant-like compounds should be used. (e.g., rAC coupled to a highly immunogenic macromolecule). With the protocols used to date, the predominant immune response generated was of the IgM type. Essentially, no IgG MABs were detected.				
14. SUBJECT TERMS RA I, SBIR, Antibody, Toxins, BL2, BD			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Mark C. Glassy
Principal Investigator's Signature

8/14/93

Date

TABLE OF CONTENTS

<u>TITLE</u>	<u>PAGE NO.</u>
Introduction	1
Methods	2
Results	4
Conclusions	10

DTIC QUALITY INSPECTED 1

Accession For	
NTIS GRA&I	<input type="checkbox"/>
DTIC TAB	<input checked="" type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist.	Avail and/or Special
E-4	

INTRODUCTION

No specific treatment regime exists for a large number of biological toxins. These toxins pose a threat in a military context and also constitute a public health hazard, mainly when accidentally ingested. An important class of biological toxins are those which inhibit protein synthesis, found in plants as well as bacteria. Many of these share structural and mechanistic properties. They are proteins, often of about 60,000 MW, with two subunits, one responsible for binding to cells, the other for the toxic action. The most common targets of these toxins are in ribosomes and the most toxic of the substances kill at one molecule per cell.

HYGEIA Pharmaceuticals develops human monoclonal antibodies for use as therapeutic agents. The purpose of this study, was to begin to use ricin as a model system for the development of human monoclonal antibodies with the ability to neutralize biological toxins. The approach was to perform in vitro immunizations of human lymphocytes and to fuse these with a proprietary human fusion partner. Resulting hybridomas are to be cloned and assayed for antigen recognition and for the neutralization of ricin in model systems.

METHODS

1. Materials:

- a. human spleenocytes: these were obtained from normal donors. No specific information is available on these patients.
- b. Supernatant of pokeweed mitogen (PWM) stimulated T-cells. T-lymphocytes from normal donors were used to generate this source of growth factors. Critical for IVI protocols.
- c. Ricin A chain (rAc)

Three forms of the antigen were used.

- rAc-g.....i) glycosylated A chain (obtained from Sigma)
- rAc-ng....ii) deglycosylated A chain (obtained from Sigma)
- rAc-p.....iii) "active peptide" of rAc (obtained from Dr. Paul Lemley) (used in ELISA screens)
- d. SHFP-1: proprietary human fusion partner.
- e. Tetanus Toxin (used as internal control to verify the IVI protocol was effective).

2. Variables tested

a. Source of spleenocytes:

- i) Spleenocytes from three separate patients were analyzed. All gave similar results. (It is unknown whether additional/different patient's spleenocytes would yield similar results.)
- ii) the concentrations of spleenocytes used were varied, with no significant difference observable. We used the following in 96-well plates.

1 x 10⁵ cells/well - low
2 x 10⁵ cells/well - medium
5 x 10⁵ cells/well - high cell density

b. rAc concentration

<u>stock</u>	<u>final concentration</u>
1 ug/ml	100 ng antigen
5 ug/ml	500 ng antigen
10 ug/ml	1 ug antigen

50 ug/ml
100 ug/ml

5 ug antigen
10 ug antigen

*100 ul of the stock rAc was added per well

*amount of rAc per well of 96-well plate

- c. PWN-T cell supernatant (PWM = pokeweed mitogen)
- o T-lymphocytes from two separate patients were obtained and incubated with PWM.
 - o harvested supernatants were aliquoted and stored at -70° C.
- two concentrations were used:
25% V/V
50% V/V
- d. days in culture
- o IVI protocols are dependent upon the time of exposure to all the critical components.
 - o we analyzed the IVI human immune response over a 4 week period.
 - o results suggest that optimizing 1) cell viability and 2) effective immune response is maximal at 6 days after initiating culture conditions.

RESULTS

The first objective of this project was to test the feasibility of using current in vitro immunization (IVI) procedures, as applied to human monoclonal antibody technology, to generate a human immune response to the ricin toxin molecule. The second objective was to successfully immortalize the human immune response to generate HuMAbs to ricin A chain.

Experimental conditions:

- 1) Condition A
 - a) 50% PWM-T spnt
 - b) [rAc-g] 100ng, 500ng, 1ug, 5ug, 10ug
 - c) 6 day incubation
- 2) Condition B
 - a) 50% PWM-T
 - b) [rAc-ng] 100ng, 500ng, 1ug, 5ug, 10ug
 - c) 6 day incubation
- 3) Condition C
 - a) 25% PWM-T
 - b) [rAc-g] 1ug, 10ug, 100ug
 - c) 6 day incubation
- 4) Condition D
 - a) 50% PWM-T
 - b) [rAc-g] 100ng, 500ng, 1ug, 5ug, 10ug
 - c) harvest well supernatant on days 4, 5, 6 & 7

The data suggests there is no major difference between 25% and 50% PWM-T cell supernatant. Best results are at 6 day incubation; day 4 & 5 yield suboptimal results. Antibody activity, cell viability decreases beyond 7 days.

No major differences were observed between glycosylated and non-glycosylated ricin A-chain forms. (Data suggests immunoreactive rAc epitopes are protein and not carbohydrate.)

Isotopes of Human Immune Response from IVI Protocol


<u>Spleenocyte</u> <u>Source</u>	<u>Protocol</u>	<u>Immunoglobulin Isotope, %</u>	
		<u>IgM</u>	<u>IgG</u>
Patient 1	IVI	33%	11%
	no IVI	0%	0%
Patient 2	IVI	44%	0%
	no IVI	11%	0%
Patient 3	IVI	44%	0%
		11%	0%

*[(number of specific isotype-secreting, immunoreactive wells)/(number of wells plated)] x 100

Experimental Condition	Reactivity (IgM) ^a			Reactivity (IgG) ^a		
	rAc-g ^a	rAc-ng ^a	rAc-p ^a	rAc-g ^a	rAc-ng ^a	rAc-p ^a
exp 1	-	-	-	-	-	-
2	+	+	-	-	-	-
3	+	+	+	-	-	-
4	+	+	+	+	+	-
5	-	-	-	-	-	-

^areactive antibody is any supernatant from a 96-well plate which reacted with the target antigen in a standard ELISA ("+"; > 2 x over background; "-" ; < 2 x background)

^ag = glycosylated
ng = nonglycosylated
p = peptide



After 6 days in culture (see Condition "B" on page 4), supernatants were harvested and analyzed by EIA for human IgM and human IgG response to rAc. This target antigen was rAc-g and rAc-ng; no difference was observed between IgM and IgG response.

Results indicate that the best concentration of rAc to use for IVI is 1ug/ml. There did not appear to be any significant difference between splenocytes from the different patients used in this experiment.

In a final experiment, spleenocytes from patient #1 were used for immortalization. The experimental procedure was fused with SHFP-1 using standard hybridoma technology. After approximately 14 days post-fusion, supernatants from developed hybridomas were screened against rAc by ELISA. Though there were IgM secreting hybridomas, the reactivity of these MAbs to rAc was weak.

Fusion Summary:

	<u>Patient 1^a</u>	<u>no-IVI Control^b</u>
# of clones/# wells plated (%)	39/192 (20%)	4/48 (8%)
#Ig isotope clones	IgM: 35 IgG: 4	IgM: 4 IgG: 0
rAc reactive clones	8 ^c	0

^aIVI protocol for this patient's spleenocytes was 'Condition B'

^bpatient's spleenocytes used as a control with no IVI setup

^csupernatants from 8 hybridomas showed weak reactivity by ELISA to rAc. During expansion of clones, antibody activity was lost. [Possibility exists that these hybridomas may have recognized EIA plates and/or FCS antigens.]

CONCLUSIONS

This SBIR project was broken down into two separate phases. The first phase was to demonstrate that a human immune response could be generated to the A-chain of ricin. The second phase centered on the immortalization of this immune response.

Two unanticipated problems were encountered. The first was the high percentage of non-specific binding to EIA plates. In essence, culture supernatants showed excessive reactivity to wells of 96-well plates which did not receive any rAc antigen. (Note: the plastic of 96-well plates, polystyrene, has exposed phenyl rings which evidently share common epitope structure with most proteins (such as PHE & TYR residues) creating non-specific binding; this was overcome by excessive blocking with albumin and tween-80).

The second problem involved the recognition of the protein antigens naturally present in fetal calf serum. FCS is necessary for spleenocyte growth and proliferation. Most of the generated IVI immune response was focused on the proteins present in FCS. This can be somewhat overcome by dosing out the target antigen whereby the immune response to FCS antigens is minimized.

We conclude that it was possible to observe a human immune response to ricin A-Chain using in vitro immunization protocols. There is variability in the response of different patient's spleenocytes to IVI/rAc protocols. We suggest that, to further improve the human immune response to ricin A-chain, different adjuvant-like compounds should be used. (e.g., rAc coupled to a highly immunogenic macromolecule)

In these experiments, the predominant immune response generated was of the IgM type. We suggest that additional patients, the use of adjuvant-like compounds discussed above, or variations in the screening protocols should allow the isolation of IgG specific clones.